Abstract
Mutations in the p53 gene are the most common genetic alterations found in human tumours, and these mutations result in high levels of p53 protein in the tumour cells. Since the expression levels of wild-type p53 in nonmalignant tissue are usually much lower in contrast, the p53 protein is an attractive target for cancer immunotherapy. We tested p53 encoded HLA-A24 binding peptides for their capacity to elicit anti-tumour cytotoxic T lymphocytes (CTL) in vitro. These peptides were in murine p53-derived cytotoxic peptides, which were being presented to CTL by H-2Kdand H-2Kbmolecules, because the HLA-A24 peptide binding motifs were similar to the H-2Kdand H-2Kb. For CTL induction, we used CD8+T lymphocytes from the peripheral blood mononuclear cells (PBMC) of healthy donors and the peptides from pulsed dendritic cells as antigen-presenting cells. We identified the peptide, p53-161 (AIYKQSQHM), which was capable of eliciting CTL lines that lysed tumour cells expressing HLA-A24 and p53. The effectors lysed C1RA24 cells (p53+, HLA-A*2402 transfectant), but not their parental cell lines C1R (p53+, HLA-A,B null cell). These results strongly indicate that the CTL exerts cytotoxic activity in HLA-A24’s restricted manner. The identification of this novel p53 epitope for CTL offers the possibility to design and develop specific immunotherapeutic approaches for treating tumours with p53 mutation in HLA-A24-positive patients. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH and Economou JS (1999) Generation of human T cell responses to an HLA A2.1 restricted peptide epitope derived from α Fetoprotein. Cancer Res 59: 3134–3142
Campo E, de la Calle Martin O, Miquel R, Palacin A, Romero M, Fabregat V, Vives J, Cardesa A and Yague J (1991) Loss of Heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 51: 4436–4442
Celis E, Tsai V, Crimi C, Demars R, Wentworth PA, Chesnut RW, Grey HM, Sette A and Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Nat Acad Sci 91: 2105–2109
Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL and DeLeo AB (1999) Generation of anti p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 5: 1281–1288
DeLeo AB, Jay G, Appella E, Dubois DC, Low LW and Old LJ (1979) Identification of a transformation related protein in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 76: 2420–2424
Fujie T, Tahara K, Tanaka F, Mori M, Takesako K and Akiyoshi T (1999) A MAGE 1 encoded HLA A24 binding synthetic peptide induces specific anti tumor cytotoxic T lymphocytes. Int J Cancer 80: 169–172
Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG and Choppin J (1998) Accumulation of the p53 protein allows recognition by human CTL of a wild type p53 epitope presented by breast carcinomas and melanomas. J Immunol 160: 328–333
Harris CC (1996) Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442–1455
Hernandez J, Lee PP, Davis MM and Sherman LA (2000) The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on TCR repertoire. J Immunol 164: 596–602
Kikuchi M, Nakao M, Inoue T, Matsunaga K, Shichijo S, Yamana H and Itoh K (1999) Identification of a SART 1 derived peptide capable of inducing HLA A24 restricted and tumor specific cytotoxic T lymphocytes. Int J Cancer 81: 459–466
Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H, Bodnar WM, Davis TA and Hunt DF (1994) Definition of specific peptide motifs for four major HLA A alleles. J Immunol 152: 3913–3924
Lee KH, Wang E, Nielsen MB, Wunderlich J, Migules S, Connors M, Steinberg SM, Rosenberg SA and Marincola FM (1999) Increased vaccine specific T cell frequency after peptide based vaccination correlates with increased susceptibility to in vitro stimulation but dose not lead to tumor regression. J Immunol 163: 6292–6300
Maric M and Liu Y (1994) Strong cytotoxic T Lymphocyte responses to a macrophage inflammatory protein 1 α expressing tumor: Linkage between inflammation and specific immunity. Cancer Res 59: 5549–5553
Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R and Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63: 883–885
Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E and DeLeo AB (1996) Therapy of murine tumor with p53 wild type and mutant sequence peptide based vaccines. J Exp Med 183: 1357–1365
McCarty TM, Liu X, Sun J, Peralta EA, Diamond DJ and Ellenhorn JDI (1998) Targeting p53 for adoptive T cell immunotherapy. Cancer Res 58: 2601–2605
Morse MA, Deng Y, Coleman D, Hull S, Fisher EK, Nair S, Schlom J and Ryback ME (1999) A phase 1 study of immunotherapy with Carcinoembryonic antigen peptide (CAP 1) pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5: 1331–1338
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D (1998) Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. Nature Med 4: 328–332
Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K and Kato I (1999) Identification of HLA-A24 epitope peptide of carcinoembryonic antigen which induce tumor reactive cytotoxic T lymphocyte. Int J Cancer 80: 92–97
Oiso M, Eura M, Katsura F, Takiguti M, Sobao Y, Masuyama K, Nakashima M, Itoh K and Ishikawa T (1999) A newly identified MAGE 3 derived epitope recognized by HLA A24 restricted cytotoxic T lymphocytes. Int J Cancer 81: 387–394
Romani N and Gruner S (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83–93
Ropke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L, Svejgaard A, van der Burg S, Nijman HW, Melief CJM and Claesson MH (1996) Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild type p53 derived peptide. Proc Natl Acad Sci USA 93: 14704–14707
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL and White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine 4: 321–327
Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E and Levine AJ (1996) p53 as a target for cancer vaccines: Recombinant canarypox virus vectors exoressing p53 protect mice against lethal tumor. Proc Natl Acad Sci USA 93: 4781–4786
Salgaller ML, Marincola FM, Cormier JN and Rosenberg SA (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56: 4749–4745
Schwarz RE, McCarty TM, Peralta EA, Diamond DJ and Ellenhorn JDI (1999) An orthotopic in vivo model of human pancreatic cancer. Surgery 126: 562–567
Storkus WJ, Zeh, III HJ, Salter RD and Lotze MT (1993) Identification of T cell epitopes: Rapid isolation of class I presented peptides from viable cells by mild acid elution. J Immunother 14: 94–103
Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E and Akiyoshi T (1997) Induction of antitumor cytotoxic T lymphocytes with a MAGE 3 encoded synthetic peptide presented by human leukocytes antigen A24. Cancer Res 57: 4465–4468
Theobald M, Biggs J, Dittmer D, Levine AJ and Sherman LA (1995) Tageting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92: 11993–11997
Theobald M, Biggs J, Hernandez J, Lastgarten J, Labadie C and Sherman LA (1997) Tolerance to p53 by A2.1 restricted cytotoxic T lymphocytes. J Exp Med 185: 833–841
Theobald M, Ruppert T, Kuckelkorn U, Hernandez J, Haussler A, Ferreira EA, Koszinowski UH, Kloetzel PM and Sherman LA (1998) The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 188: 1017–1028
van den Burg SH, Ras E, Drijfhout JW, Benckhuijsen WE, Bremers AJA, Melief CJM and Kast WM (1995) An HLA class 1 peptide binding assay based on competition for binding to class 1 molecules on intact human B cells, Identification of conserved HIV 1 Polymerase peptides binding to HLA A0301. Hum Immunol 44: 189–198
van der Burg SH, Visseren MJW, Brandt RMP, Kast WM and Melief CJM (1996) Immunogenicity of peptides bound to MHC class I molecules depends on the MHC peptide complex stability. J Immunol 156: 3308–3314
Vierboom MPM, Nijman HW, Offrnga R, van der Voort EIH, van Hall T, van den Broek L, Fleuren G, Kenemans P, Kast WM and Melief CJM (1997) Tumor eradication by wild type p53 specific cytotoxic T lymphocytes. J Exp Med 186: 695–704
Vissers JLM, De Vries IJM, Schreurs MWJ, Engelen LPH, Oosterwijk E, Figdor CG and Adema GJ (1999) The renal cell carcinoma associated antigen G250 encodes a human leukocyte antigen HLA A2.1 restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59: 5554–5559
Walter EA (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N Engl J Med 333: 1038–1044
Wang F, Bade E, Kuniyoshi C, Sppears L, Jeffery G, Marty V, Groshen S and Weber J (1999) Phase 1 trial of a MART 1 peptide vaccine with incomplete Freund’s adjuvant for resected high risk melanoma. Clin Cancer Res 5: 2756–2765
Weller M (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292: 435–445
Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Mastumoto H, Mori K, Hayashi A, Ymana H, Shirouzu K and Itoh K (1999) Identification of a gene cording for a protein possessing shared tumor epitopes capable of inducing HLA–A24–restricted Cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056–4063
Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD and Berzofsky JA (1993) A mutant p53 tumor suppressor protein is a target for peptide induced CD8+ cytotoxic T cells. Cancer Res 53: 3257–3261
Yu Z, Liu X, McCarty TM, Diamond DJ and Ellenhorn JDI (1997) The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J Surg Res 69: 337–343
Zhou X, Wong S, Walter J, Jacks T and Eisen HN (1999) Increased generation of CD8+ T cell clones in p53 mutant mice. J Immunol 162: 3957–3960
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Umano, Y., Tsunoda, T., Tanaka, H. et al. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 84, 1052–1057 (2001). https://doi.org/10.1054/bjoc.2000.1715
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1715
Keywords
This article is cited by
-
Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
Nature Communications (2019)
-
Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma
Cancer Immunology, Immunotherapy (2019)
-
P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma
Cancer Immunology, Immunotherapy (2014)
-
Immunologic aspect of ovarian cancer and p53 as tumor antigen
Journal of Translational Medicine (2005)
-
A listing of human tumor antigens recognized by T cells: March 2004 update
Cancer Immunology, Immunotherapy (2005)